Bibliometric analysis of research hotspots and frontier trends in skin adverse reactions caused by epidermal growth factor receptor inhibitors in the treatment of lung cancer
10.16753/j.cnki.1008-2344.2024.06.005
- VernacularTitle:肺癌与表皮生长因子受体抑制剂相关皮肤不良反应的研究热点与趋势的文献计量学分析
- Author:
Kailun HUANG
1
;
Han WANG
;
Lingjing ZENG
;
Lingna YOU
;
Yilan WU
Author Information
1. 福建中医药大学护理学院,福建 福州 350122
- Keywords:
lung cancer;
epidermal growth factor receptor inhibitors;
skin adverse reactions;
bibliometrics
- From:
Journal of Shenyang Medical College
2024;26(6):582-588,643
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the research hotspots and frontier trends in skin adverse reactions caused by epidermal growth factor receptor inhibitors(EGFRIs)in the treatment of lung cancer.Methods:CiteSpace software was used to visually analyze the literature on skin adverse reactions caused by EGFRIs in the treatment of lung cancer in the three databases of CNKI,WANFANG and VIP from the establishment of the database to October 30,2023.The literature was analyzed from the aspects of annual publication volume,funding,journals,authors,keywords,etc.Results:A total of 663 Chinese literature were obtained,with national funding projects accounting for 9.20%.A total of 312 journals were involved,with the highest publication volume being the Chinese Journal of Lung Cancer,accounting for 2.71%.The China-Japan Friendship Hospital and the Beijing University of Chinese Medicine were the top two research institutions in terms of the number of published papers,and they had a close cooperation relationship.The top three authors in terms of publication volume were CUI Huijuan with 18 articles,PENG Yanmei with 11 articles,and ZHANG Xu with 9 articles.Research hotspots focus on EGFRIs related rash,gefitinib,and clinical efficacy.Frontier trends focused on the clinical observation,research progress,and traditional Chinese medicine of skin adverse reactions caused by EGFRIs drugs.Conclusions:The research on skin adverse reactions caused by EGFRIs in the treatment of lung cancer has great development prospects.Authors and institutions can further form a stronger collaborative network to promote interdisciplinary communication,and jointly promote research and development in this field.
